Stock Analysis, Dividends, Split History

CFCO / CF Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price9.88
Volume302,400.00
Market Cap ($M)2,117.98
Enterprise Value ($M)407.98
Book Value ($M)1,338.00
Book Value / Share6.24
Price / Book1.58
NCAV ($M)-28,692.00
NCAV / Share-133.84
Price / NCAV-0.07
Share Statistics
Preferred Stock Shares Outstanding 375,000
Common Shares Outstanding 214,370,000
Common Stock Shares Outstanding 214,370,000
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.10
Return on Assets (ROA)0.32
Return on Equity (ROE)44.60
Balance Sheet (mrq) ($M)
Assets30,030.00
Liabilities28,692.00
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenue From Related Parties0.00
Revenues0.00
Net Income223.00
Cash Flow Statement (mra) ($M)
Identifiers and Descriptors
CUSIPG20307107
Central Index Key (CIK)1668428
Industry Groups

Split History

Stock splits are used by CF Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Savara Inc. (SVRA) CEO Rob Neville on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Welcome to the Savara Conference Call. At this time, all participants are in listen-only mode. An audio webcast of this call will be available on the Investors Section of Savara’s website at www.savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction or transmission of this call without the expressed written consent of Savara is strictly prohibited. (16-1)

The Zacks Analyst Blog Highlights: Rosehill Resources, FGL Holdings, Glu Mobile, inTest and Francesca???s Holdings

2018-08-08 zacks
Chicago, IL – August 8, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Rosehill Resources Inc. (ROSE - Free Report) , FGL Holdings (FG - Free Report) , Glu Mobile Inc. (GLUU - Free Report) , inTest Corporation (INTT - Free Report) and Francesca’s Holdings Corporation (FRAN - Free Report) . (5-0)

Verona Pharma plc's (VRNA) CEO Jan-Anders Karlsson on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Verona Pharma plc (NASDAQ:VRNA) Q2 2018 Results Earnings Conference Call August 7, 2018 8:00 AM ET

5 of the Best Stocks Under $10 for 2018

2018-08-07 zacks
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive,” and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors. (0-1)

Top 10 Stocks Under $20

2018-07-25 zacks
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors. (4-2)

CUSIP: G20307107